These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32358739)

  • 1. Effective improvement of minimal change nephrotic syndrome with uncontrollable high low-density lipoprotein cholesterol level using evolocumab accompanied by the development of acute pancreatitis.
    Asai R; Kaneko T; Seki M; Tsuruoka S
    CEN Case Rep; 2020 Nov; 9(4):333-337. PubMed ID: 32358739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete remission of minimal change nephrotic syndrome with type 2 diabetes mellitus treated by microemulsion formulation of cyclosporin and fluvastatin].
    Makibayashi K; Fukatsu A; Kita T
    Nihon Jinzo Gakkai Shi; 2002 Mar; 44(2):109-13. PubMed ID: 11974950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
    Awanami Y; Fukuda M; Nonaka Y; Takashima T; Matsumoto K; Yamasaki M; Miyazono M; Ikeda Y
    BMC Nephrol; 2017 Jul; 18(1):221. PubMed ID: 28683788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report.
    Nishizono R; Kogou H; Ishizaki Y; Minakawa A; Kikuchi M; Inagaki H; Sato Y; Fujimoto S
    BMC Nephrol; 2020 Sep; 21(1):410. PubMed ID: 32967631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of high-age minimal change nephrotic syndrome relapse after 18-year remission and effective treatment with steroid and cyclosporin combined therapy].
    Yoshimoto K; Wada T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Yokoyama H; Kobayashi K
    Nihon Jinzo Gakkai Shi; 2000 Oct; 42(8):640-3. PubMed ID: 11195400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults.
    Fujiwara A; Hirawa N; Kobayashi Y; Yatsu K; Katsumata M; Ehara Y; Okuyama Y; Yutoh J; Kaneda T; Fujita M; Yamamoto Y; Saka S; Toya Y; Yasuda G; Umemura S
    Clin Exp Nephrol; 2015 Apr; 19(2):240-6. PubMed ID: 24771147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
    Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S
    Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment].
    Okada T; Takahashi H; Ogura M; Nakao T; Shimizu T
    Nihon Jinzo Gakkai Shi; 1996 Jan; 38(1):46-51. PubMed ID: 8855137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous remission of therapy-resistant minimal change nephritis in an adult woman 12 years after onset of the disease.
    Raml A; Sedlak M; Schmekal B; Stuby U; Syre' G; Biesenbach G
    Wien Med Wochenschr; 2006 Jul; 156(13-14):421-5. PubMed ID: 16937046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer.
    Ishibuchi K; Iwakura T; Kaneko M; Fukasawa H; Furuya R
    CEN Case Rep; 2020 Aug; 9(3):215-219. PubMed ID: 32170578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent minimal change disease and retroperitoneal liposarcoma successfully treated by tumor resection and steroid therapy.
    Yasui Y; Shibata R; Morita N; Himuro N; Hamauchi A; Watanabe M; Ito K; Yasuno T; Abe Y; Miyake K; Yoshimura F; Hamsaki M; Hisano S; Masutani K; Nakashima H
    CEN Case Rep; 2021 Feb; 10(1):94-99. PubMed ID: 32902814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case reports of low dose cyclosporine. A therapy in adult minimal change nephrotic syndrome.
    Woo KT; Chew ST; Vathsala A; Chiang GS
    Ann Acad Med Singap; 2001 Jul; 30(4):430-5. PubMed ID: 11503553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
    Li T; Zhang Y; Cong H
    BMC Cardiovasc Disord; 2021 Jan; 21(1):19. PubMed ID: 33413096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
    Koskinas KC; Windecker S; Pedrazzini G; Mueller C; Cook S; Matter CM; Muller O; Häner J; Gencer B; Crljenica C; Amini P; Deckarm O; Iglesias JF; Räber L; Heg D; Mach F
    J Am Coll Cardiol; 2019 Nov; 74(20):2452-2462. PubMed ID: 31479722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minimal change nephrotic syndrome complicated with recurrence of malignant thymoma: an interesting case with remission due to steroid therapy of both nephrotic syndrome and thymoma].
    Fukuda A; Sato Y; Iwatsubo S; Komatsu H; Nishiura R; Fukudome K; Yamada K; Hara S; Fujimoto S; Kitamura K
    Nihon Jinzo Gakkai Shi; 2009; 51(2):130-7. PubMed ID: 19378799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.